Extends ALS research funding through 2031

Congress approved bill hr8205-119 ("Extends ALS research funding through 2031"). Last action: November 3, 2026.

Congress file hr8205-119, before Congress. Passed as of 2026-11-03.

What it does

Five more years of federal grants for ALS drug research. The NIH and FDA will continue funding scientists working on new treatments and investigational drugs for ALS patients through 2031, five years longer than planned.

The bigger picture

Faster drug development and safety checks across neurodegenerative diseases. The FDA must now create and publish a detailed five-year action plan for speeding up approval of treatments for ALS and other rare brain diseases like Parkinson's and Huntington's.

What to watch

Safety reports must meet federal timeline but oversight gaps possible. While researchers must now report serious side effects quickly, there is no explicit funding boost specified for FDA staff to review these reports on time.

Official summary

This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.The bill reauthorizesgrants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, anda Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate

Read the official record for hr8205-119

See everything up for a vote · This week in Congress · See what we have filed with the clerk